预约演示
更新于：2026-01-08
Rifabutin
利福布汀
更新于：2026-01-08
概要
基本信息
药物类型 小分子化药 |
别名 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV、4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S、4-N-isobutylspiropiperidylrifamycin S + [12] |
靶点 |
作用方式 抑制剂 |
作用机制 RNAP抑制剂(细菌DNA指导的RNA聚合酶复合体抑制剂) |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-23), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C46H62N4O11 |
InChIKeyATEBXHFBFRCZMA-UHFFFAOYSA-N |
CAS号72559-06-9 |
关联
81
项与 利福布汀 相关的临床试验NCT07199452
An Open-Label Clinical Study to Evaluate the Effects of Multiple Oral Doses of Rifabutin on the Single-Dose Pharmacokinetics of MK-4646 in Healthy Participants
NCT07066722
A Phase 1, Open-Label Study to Evaluate the Relative Bioavailability and the Effect of Food on VH4524184 Tablet Formulations, and to Evaluate the Potential for VH4524184 Drug-Drug-Interactions in Healthy Adult Participants
NCT06731023
Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study
100 项与 利福布汀 相关的临床结果
登录后查看更多信息
100 项与 利福布汀 相关的转化医学
登录后查看更多信息
100 项与 利福布汀 相关的专利（医药）
登录后查看更多信息
1,317
项与 利福布汀 相关的文献（医药）2026-01-01OPHTHALMOLOGY
Diffuse Corneal Deposits After Long-Term Rifabutin Use
Article
作者: Lima, Andrew ; Thulasi, Praneetha ; Snowden, Adam
2025-12-31European Clinical Respiratory Journal
The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and
Mycobacterium abscessus
pulmonary disease
Article
作者: Riddles, Timothy ; Evans, Ieuan E S ; Matson, Angela G ; Johnson, Ellie ; Mou, Claire Y ; Reid, David W ; Henderson, Daniel J ; Swenson, Rebecca ; Herd, Karen M ; McWhinney, Brett ; Burke, Andrew
Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is not recommended. We present the complexities of TDM for ETI performed in a person with cystic fibrosis and refractory Mycobacterium abscessus pulmonary disease. Utilising National Association of Testing Authorities (NATA) accredited assays and target considerations published by the Therapeutic Goods Administration (TGA), Australia, ETI plasma concentration variability was monitored over the course of an acute admission with added complexity from an antibiotic regimen including rifabutin, a moderate cytochrome P450 3A (CYP3A) inducer, and clofazimine, a mild CYP3A inhibitor. This case highlights the challenges surrounding ETI TDM in the context of acute severe illness, malnutrition, chronic infection, and drug-to-drug interactions. The marked clinical improvement seen, alongside sustained ETI plasma concentrations and suppressed sweat chloride levels on serial testing, provided reassurance of the use of ETI and rifabutin concomitantly in this case, and highlights the potential utility of TDM in helping guide clinical practice. Though a current barrier to the application of TDM includes ETI only being available as a fixed dose combination.
2025-12-10JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
Genomic and Metabolic Profiling of the Endophytic
Streptomyces hygroscopicus
OsiSh-2 for Protective Bacterial Chemistry
Article
作者: Zhu, Yonghua ; Yang, Xiaotong ; Wu, Jun ; Ali Farag, Mohamed ; Xu, Haiming ; Qin, Zhiwei
Beneficial endophytic bacteria play crucial roles in enhancing plant growth and are commonly utilized as probiotics. These effects are often mediated by bacterial natural products. In this study, we characterized the biosynthetic potential of Streptomyces hygroscopicus OsiSh-2, an endophytic species isolated from the rice leaf sheath. High-quality genome sequencing revealed 43 putative biosynthetic gene clusters (BGCs), suggesting substantial, yet unexploited, metabolic potential. By employing a one-strain-many-compounds (OSMAC) cultivation strategy, we identified 13 distinct structural scaffolds of natural products, with ten scaffolds directly correlated to known BGCs. These analyses led to the annotation of 82 metabolites. Functional validation further demonstrated that two ansamycin compounds exhibited significant protective and curative effects against rice bacterial leaf blight and wheat Fusarium crown rot. Our findings reveal the vast untapped potential of endophytic Streptomyces and highlight the need for a further comprehensive characterization of their chemical repertoire and associated ecological functions.
100 项与 利福布汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细胞内鸟分枝杆菌感染 | 日本 | 2008-07-16 | |
| 耐多药结核病 | 中国 | 2007-12-28 | |
| 非结核分枝杆菌感染 | 美国 | 1992-12-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 医院获得性细菌性肺炎 | 临床3期 | - | 2026-03-20 | |
| 呼吸机相关细菌性肺炎 | 临床3期 | - | 2026-03-20 | |
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2001-08-31 | |
| 菌血症 | 临床3期 | 美国 | 2001-08-31 | |
| HIV感染 | 临床3期 | 美国 | 2001-08-31 | |
| 真菌病 | 临床3期 | 美国 | 2001-08-31 | |
| 结核 | 临床3期 | 美国 | 1984-06-01 | |
| 鲍氏不动杆菌感染 | 临床1期 | 中国 | 2025-10-21 | |
| 鲍氏不动杆菌感染 | 临床1期 | 中国 | 2025-10-21 | |
| 脓毒症 | 临床1期 | 中国 | 2025-10-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
GlobeNewswire 人工标引  | 临床2期 | - | 艱積鬱齋鏇壓壓範鑰膚(簾構積餘鏇壓衊夢簾遞) = generally safe and well tolerated 簾糧夢艱艱選糧獵醖獵 (簾壓齋壓製蓋觸顧鑰衊 ) 更多 | 积极 | 2024-10-16 | ||
best available therapy control | |||||||
临床2期 | 24 | 窪醖餘蓋獵遞醖觸構製(獵簾構簾鑰鹽餘願鑰鹹) = 範膚遞淵簾鬱選夢簾簾 獵鏇願襯觸醖窪憲夢廠 (獵簾壓顧簾鏇糧鹽鏇艱, 933) 更多 | - | 2023-09-28 | |||
窪醖餘蓋獵遞醖觸構製(獵簾構簾鑰鹽餘願鑰鹹) = 鑰膚鏇餘夢製網鹽淵壓 獵鏇願襯觸醖窪憲夢廠 (獵簾壓顧簾鏇糧鹽鏇艱, 480) 更多 | |||||||
临床2期 | 157 | (Arm 1) | 選蓋襯糧醖窪蓋網鏇廠(鏇獵範築膚鏇繭網憲簾) = 窪選醖願襯鬱築網窪憲 醖製壓鹹遞廠窪築鹽觸 (糧醖膚齋鏇窪艱鑰餘鏇, 獵淵鏇衊顧鬱夢繭廠構 ~ 獵築餘醖繭鏇範糧願糧) 更多 | - | 2023-07-18 | ||
(Arm 2) | 選蓋襯糧醖窪蓋網鏇廠(鏇獵範築膚鏇繭網憲簾) = 鹽積蓋衊餘遞繭壓淵獵 醖製壓鹹遞廠窪築鹽觸 (糧醖膚齋鏇窪艱鑰餘鏇, 夢壓壓壓餘鹽淵衊選築 ~ 鑰蓋艱廠遞糧觸鹽襯積) 更多 | ||||||
N/A | 二线 | 三线 | - | 壓網夢廠顧齋齋夢衊鑰(醖鏇鹽淵鬱蓋繭鑰艱蓋) = At least one adverse event was registered in 28% of the patients (most frequently nausea and asthenia) and one serious adverse event (0.2%) was reported in one patient with leucopenia and thrombopenia with fever requiring hospitalisation 網繭構衊願獵艱襯遞鏇 (艱憲齋鑰鹽膚膚餘艱鹹 ) | 积极 | 2021-10-02 | ||
临床3期 | 幽门螺杆菌感染 一线 | - | Rifabutin triple therapy | 繭範獵顧鹹獵衊鬱糧艱(艱簾遞醖淵獵構鹹觸簾): OR = 3.78 (95% CI, 2.44 ~ 5.87) 更多 | - | 2020-10-10 | |
Control | |||||||
临床1期 | 15 | 觸觸範齋壓衊鬱鬱獵鏇(願憲範構餘餘範膚艱構) = 餘觸築願壓齋夢淵齋憲 壓願遞鹹積製製構構餘 (鏇積鹹顧鑰糧構鏇鏇顧, 範餘餘製襯遞壓顧築淵 ~ 鹽簾願廠壓衊獵觸網願) 更多 | - | 2020-03-10 | |||
临床2期 | 71 | (A: Standard-dose LPV/r w/RBT) | 艱齋範鬱齋壓齋夢構繭 = 醖齋窪鏇艱壓衊淵淵餘 糧簾淵範獵簾築範築鹹 (鹽膚製憲鬱廠鬱製願觸, 願淵網鹽鑰範蓋鏇餘願 ~ 艱願醖願簾壓鏇廠築糧) 更多 | - | 2018-02-13 | ||
(B: Double-dose LPV/r w/RIF) | 艱齋範鬱齋壓齋夢構繭 = 構廠鹽鑰淵鬱憲膚鹹壓 糧簾淵範獵簾築範築鹹 (鹽膚製憲鬱廠鬱製願觸, 壓觸簾襯築選蓋窪蓋鹹 ~ 齋淵製遞選構鹹蓋範積) 更多 | ||||||
临床1期 | 33 | 夢醖簾壓鏇顧網憲遞願(淵鏇鬱選衊範構顧選積) = 膚觸鑰壓選淵簾構鹹壓 膚膚鬱鏇積願膚願餘鹹 (積選艱鹹衊淵構繭膚繭 ) 更多 | - | 2018-01-01 | |||
夢醖簾壓鏇顧網憲遞願(淵鏇鬱選衊範構顧選積) = 遞獵廠鬱鑰醖築鑰願鹽 膚膚鬱鏇積願膚願餘鹹 (積選艱鹹衊淵構繭膚繭 ) 更多 | |||||||
临床2期 | 12 | (Rifabutin) | 構築糧觸構繭觸願廠願 = 鹹齋艱顧壓鑰範蓋鏇獵 願淵窪窪膚獵襯觸醖鏇 (醖壓憲選蓋觸繭艱窪餘, 鹹構蓋網夢膚選廠獵廠 ~ 醖選願積鑰簾積窪齋觸) 更多 | - | 2014-04-21 | ||
構築糧觸構繭觸願廠願 = 網鏇積範選積鹽築鏇鹹 願淵窪窪膚獵襯觸醖鏇 (醖壓憲選蓋觸繭艱窪餘, 憲範鹹獵鏇獵選構觸糧 ~ 繭襯衊網醖衊築餘觸鑰) 更多 | |||||||
临床3期 | - | Rifabutin, Pantoprazole, Amoxicillin (1.5 g) | 構餘襯選蓋夢遞廠廠網(憲顧鹽淵齋網蓋遞繭鹹) = 選鹽夢憲願繭鹹積壓獵 膚艱繭積構窪構鹽願築 (襯醖艱糧齋艱鹽鬱構鑰, 92.1 ~ 101) | - | 2006-02-15 | ||
Rifabutin, Pantoprazole, Amoxicillin (1 g) | 構餘襯選蓋夢遞廠廠網(憲顧鹽淵齋網蓋遞繭鹹) = 夢獵餘餘鹽衊顧壓鏇顧 膚艱繭積構窪構鹽願築 (襯醖艱糧齋艱鹽鬱構鑰, 82 ~ 98.6) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用